MOLECULAR THERAPY

Scope & Guideline

Exploring the frontiers of molecular biology and therapy.

Introduction

Welcome to your portal for understanding MOLECULAR THERAPY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1525-0016
PublisherCELL PRESS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2000 to 2024
AbbreviationMOL THER / Mol. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139

Aims and Scopes

Molecular Therapy is a journal dedicated to advancing the understanding and application of molecular therapeutics in various fields of medicine, particularly cancer, immunotherapy, and regenerative medicine. The journal aims to publish high-quality research that contributes to the development of novel therapeutic strategies and approaches.
  1. Cancer Therapeutics and Immunotherapy:
    The journal focuses on novel approaches to cancer treatment, including immunotherapy strategies such as engineered T cells and bispecific antibodies, as well as small molecule inhibitors targeting specific pathways related to tumor growth and metastasis.
  2. Metabolic and Inflammatory Disorders:
    Research on the therapeutic effects of various compounds in metabolic and inflammatory conditions is prominent, emphasizing the role of natural products, dietary components, and synthetic compounds in modulating metabolic pathways and inflammatory responses.
  3. Neuroprotection and Neuroinflammation:
    The journal includes studies on neuroprotective agents and the mechanisms underlying neuroinflammation, particularly in relation to neurodegenerative diseases and brain injuries.
  4. Molecular Mechanisms of Drug Action:
    A significant focus is placed on elucidating the molecular mechanisms of action of various therapeutic agents, including their effects on signaling pathways, gene expression, and cellular processes.
  5. Natural Products and Traditional Medicine:
    The exploration of bioactive compounds derived from natural sources for their therapeutic potentials is a key area, with studies investigating their mechanisms of action and clinical applications.
Recent publications in Molecular Therapy indicate several emerging themes that are gaining traction within the research community. These trends reflect current scientific interests and the evolving landscape of therapeutic development.
  1. Engineered Cell Therapies:
    There is a growing focus on engineered cell therapies, particularly in cancer treatment. This includes advancements in T cell receptor engineering and bispecific antibodies, which highlight innovative approaches to enhancing immune responses against tumors.
  2. Microbiome and Gut-Brain Axis:
    Research examining the role of gut microbiota and their metabolites in brain function and pathology is emerging, reflecting an interdisciplinary approach that links microbiology, neuroscience, and therapeutic interventions.
  3. Natural Compounds in Therapy:
    An increasing number of studies are investigating the therapeutic potentials of natural compounds, emphasizing their roles in modulating complex biological pathways and their potential applications in treating various diseases.
  4. Signaling Pathways in Disease Modulation:
    A trend towards understanding the intricate signaling pathways involved in disease mechanisms is evident, with a focus on how these pathways can be targeted for therapeutic intervention.
  5. Personalized Medicine Approaches:
    Emerging themes include the development of personalized medicine strategies, particularly in cancer therapeutics, where individual genetic and molecular profiles guide treatment decisions.

Declining or Waning

While Molecular Therapy continues to explore a wide range of impactful research areas, certain themes have shown a decline in prominence over recent years. This may reflect shifts in research focus or advancements in related fields.
  1. Traditional Pharmacology:
    Research centered around traditional pharmacological approaches has decreased, possibly due to the growing interest in novel molecular mechanisms and targeted therapies that offer more precise and effective treatment options.
  2. Basic Biochemical Studies:
    There is a noted reduction in purely biochemical studies that do not directly relate to therapeutic applications. The journal appears to favor research with clear clinical implications or translational potential.
  3. Animal Models of Disease:
    Although animal studies remain important, there seems to be a waning emphasis on basic animal model research without direct therapeutic relevance, as the focus shifts towards more innovative and applicable therapeutic strategies.

Similar Journals

CURRENT MEDICINAL CHEMISTRY

Exploring Innovations in Drug Design and Discovery.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 0929-8673Frequency: 42 issues/year

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Transforming cancer research into clinical solutions.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

MOLECULAR CANCER THERAPEUTICS

Exploring the molecular mechanisms behind cancer therapies.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

JOURNAL OF MOLECULAR MEDICINE-JMM

Exploring the Intersection of Biochemistry and Clinical Innovation.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Recent Patents on Anti-Cancer Drug Discovery

Navigating the Landscape of Anti-Cancer Innovations
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

JOURNAL OF GENE MEDICINE

Advancing the Frontiers of Gene Therapy
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Molecular & Cellular Oncology

Unraveling the complexities of cancer biology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

BIOSCIENCE REPORTS

Connecting Researchers with Groundbreaking Findings
Publisher: PORTLAND PRESS LTDISSN: 0144-8463Frequency: 6 issues/year

BIOSCIENCE REPORTS, published by Portland Press Ltd, is a prestigious journal dedicated to advancing the fields of biochemistry, biophysics, cell biology, and molecular biology. Founded in 1981, the journal has established itself as a vital resource for researchers and professionals, boasting a significant impact factor and high rankings within its categories, including Q2 in Biochemistry and Q1 in Biophysics as of 2023. The journal’s commitment to high-quality, peer-reviewed research ensures that it remains an influential platform for the dissemination of cutting-edge scientific findings. While it operates under a traditional subscription model, it offers various access options to accommodate the needs of the scientific community. With ongoing publication through 2024, BIOSCIENCE REPORTS continues to play a crucial role in shaping discussions in the life sciences and fostering innovative research in biology.

MOLECULAR PHARMACOLOGY

Elevating Understanding of Molecular Drug Actions
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.